Remsima and Inflectra: new infliximab 'biosimilars'

Remsima and Inflectra are the first biosimilar monoclonal antibodies to become available in the UK.

Remsima and Inflectra have the same indications and dosing as Remicade, and are supplied in the same pharmaceutical form and strength.
Remsima and Inflectra have the same indications and dosing as Remicade, and are supplied in the same pharmaceutical form and strength.

Biosimilar medicines are so called because they have been specifically developed to be highly similar to an existing biologic medicine, in this case the anti-tumour necrosis factor (anti-TNF) antibody Remicade (infliximab).

Further information
View Remsima drug record
View Inflectra drug record
Questions about biosimilar versions of infliximab

Remsima and Inflectra are licensed for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.

Clinical trials have shown that there are no clinically meaningful differences in quality, efficacy or safety between Remsima/Inflectra and Remicade.

Both Remsima and Inflectra are available at an NHS list price of £377.66 per 100mg vial.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases